Esloray Special Precautions

Efficacy and safety in children younger than 12 months of age have not been established.
The medication may cause drowsiness in some patients. Individual response should be determined that it does not cause drowsiness before driving, operating machines or working in areas with risk of falling. In clinical trials, this medication was no more likely than placebo to cause drowsiness (for film-coated tablet only).
Be careful in patients with renal disease. In the case of severe renal insufficiency (GFR < 30 mL/min), it should be used as alternate day dosage until the physicians can determine the individual patient's response.
Serum levels of this medication may be increased when using with macrolides antimicrobials such as erythromycin or imidazole antifungal such as ketoconazole. No clinical relevant changes in desloratadine plasma concentrations were observed in multiple-dose ketoconazole and erythromycin interaction trials.
Desloratadine should be administered with caution in patients with a medical or family history of seizures. In particular, young children may be more susceptible to developing new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.
Effects on ability to drive and use machines: No effects on the ability to drive and use machines have been observed.